Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
Cytotherapy. 2013 Nov;15(11):1352-61. doi: 10.1016/j.jcyt.2013.07.004.
Adipose tissue-derived mesenchymal stromal cells (ASCs) are of interest as a cell therapeutic agent for immunologic and degenerative diseases. During in vitro expansion, ASCs may be at risk for genetic alterations, and genetic screening is a prerequisite. We examined the presence of aneuploidy in ASCs and its origin and development during culture and evaluated the implications of aneuploidy for therapeutic use of ASCs.
Adipose tissue of healthy individuals was used for isolation and expansion of ASCs. Chromosome copy numbers were studied using fluorescence in situ hybridization analysis. Aneuploidy was studied in freshly isolated ASCs, in ASCs cultured for 0-16 passages and in senescent cultures. To evaluate the plasticity of ploidy, ASCs were cloned, and the variation of ploidy in the clones was examined. Tumorigenicity was studied by subcutaneous injection of aneuploid ASCs in immunodeficient NOD/SCID mice.
No aneuploidy was detected in freshly isolated ASCs. In low passages (passages 0-4), aneuploidy was detected in 3.4% of ASCs. Prolonged culture expansion of ASCs (passages 5-16) resulted in a significant increase of aneuploidy to 7.1%. With senescence, aneuploidy increased further to 19.8%. Aneuploidy was observed in clones of diploid ASCs, demonstrating the de novo development of aneuploidy. No transformation of ASCs was observed, and in contrast to cancer cell lines, aneuploid ASCs were incapable of tumor formation in immunodeficient mice.
ASC cultures contain a stable percentage of aneuploid cells. Aneuploidy was not a predecessor of transformation or tumor formation. This finding indicates that aneuploidy is culture-induced but unlikely to compromise clinical application of ASCs.
脂肪组织来源的间充质基质细胞(ASCs)作为一种细胞治疗剂,可用于治疗免疫和退行性疾病。在体外扩增过程中,ASCs 可能存在遗传改变的风险,因此遗传筛选是必要的。本研究旨在检测 ASCs 中的非整倍体的存在及其在培养过程中的起源和发展,并评估非整倍体对 ASC 治疗应用的影响。
从健康个体的脂肪组织中分离和扩增 ASCs。使用荧光原位杂交分析研究染色体拷贝数。研究了新鲜分离的 ASCs、培养 0-16 代的 ASCs 和衰老培养物中的非整倍体。为了评估倍性的可变性,对 ASCs 进行了克隆,并检测了克隆中倍性的变化。通过向免疫缺陷 NOD/SCID 小鼠皮下注射非整倍体 ASCs 研究其致瘤性。
新鲜分离的 ASCs 中未检测到非整倍体。在低代(0-4 代)中,3.4%的 ASCs 存在非整倍体。ASCs 的长期培养扩增(5-16 代)导致非整倍体显著增加至 7.1%。随着衰老,非整倍体进一步增加至 19.8%。在二倍体 ASCs 的克隆中观察到非整倍体,表明非整倍体的新发发展。未观察到 ASCs 的转化,与癌细胞系不同,非整倍体 ASCs 不能在免疫缺陷小鼠中形成肿瘤。
ASC 培养物中含有稳定比例的非整倍体细胞。非整倍体不是转化或肿瘤形成的前兆。这一发现表明非整倍体是培养诱导的,但不太可能影响 ASC 的临床应用。